Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study

Journal of Clinical Pharmacology

Volumn 51, Issue 11, 2011, Pages 1587-1591

  Wessels, Alette M ^a   Bies, Robert R ^a,b   Pollock, Bruce G ^b,c   Schneider, Lon S ^d   Lieberman, Jeffrey A ^e   Stroup, Scott ^e   Li, Claire H ^a   Coley, Kim ^f   Kirshner, Margaret M ^c   Marder, Stephen R ^g  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e College of Physicians and Surgeons ^*  (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

population pharmacokinetics; schizophrenia; ziprasidone

Indexed keywords

ZIPRASIDONE;

ADULT; AGED; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; FOOD INTAKE; HUMAN; MAJOR CLINICAL STUDY; MALE; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; SCHIZOPHRENIA; THIAZOLES; YOUNG ADULT;

EID: 79957521017     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010387604     Document Type: Article

References (22)

1. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995 ; 275 (1). 101-113
2. Lowe JA, Seeger TF, Vinick FJ. Atypical antipsychotics: recent findings and new perspectives. Med Res Rev. 1988 ; 8 (4). 475-497
3. Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol. 2000 ; 49 (suppl 1). 35S - 42S (Pubitemid 30151051)
4. Prakash C, Kamel A, Gummerus J, Wilner K. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab Dispos. 1997 ; 25 (7). 863-872 (Pubitemid 27318605)
5. Hamelin BA, Allard S, Laplante L, et al. The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy. 1998 ; 18 (1). 9-15 (Pubitemid 28058997)
6. Miceli JJ, Wilner KD, Hansen RA, Johnson AC, Apseloff G, Gerber N. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Br J Clin Pharmacol. 2000 ; 49 (suppl 1). 5S - 13S (Pubitemid 30151047)
7. Wilner KD, Tensfeldt TG, Baris B, et al. Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol. 2000 ; 49 (suppl 1). 15S - 20S (Pubitemid 30151048)
8. Cherma MD, Reis M, Hagg S, Ahlner J, Bengtsson F. Therapeutic drug monitoring of ziprasidone in a clinical treatment setting. Ther Drug Monit. 2008 ; 30 (6). 682-688
9. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm. 1977 ; 5 (5). 445-479 (Pubitemid 8224518)
10. Keefe RS, Mohs RC, Bilder RM, et al. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr Bull. 2003 ; 29 (1). 45-55 (Pubitemid 36871056)
11. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 ; 353 (12). 1209-1223 (Pubitemid 41345943)
12. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003 ; 29 (1). 15-31 (Pubitemid 36871054)
13. Diagnostic and Statistical Manual of Mental Disorders. 4 th ed.Washington, DC: American Psychiatric Association; 1994. Washington, DC: American Psychiatric Association ; 1994 :
14. Aravagiri M, Marder SR, Pollock B. Determination of ziprasidone in human plasma by liquid chromatography-electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 ; 847 (2). 237-244 (Pubitemid 46331027)
15. Caley CF, Cooper CK. Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother. 2002 ; 36 (5). 839-851 (Pubitemid 34517416)
16. Karlsson MO, Jonsson EN, Wiltse CG, Wade JR. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm. 1998 ; 26 (2). 207-246 (Pubitemid 28496599)
17. Feng Y, Pollock BG, Coley K, et al. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol. 2008 ; 66 (5). 629-639
18. Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 2008 ; 48 (2). 157-165
19. Jin Y, Pollock BG, Coley K, et al. Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. J Clin Pharmacol. 2010 ; 50 (1). 73-80
20. Everson G, Lasseter KC, Anderson KE, et al. The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. Br J Clin Pharmacol. 2000 ; 49 (suppl 1). 21S - 6S (Pubitemid 30151049)
21. Ballas C, Yang C, O'Reardon J, Ballas P, Baldassano C. Ziprasidone: a novel psychotropic with unique properties. Expert Rev Neurother. 2004 ; 4 (2). 179-186 (Pubitemid 38315937)
22. Preskorn SH. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. Clin Pharmacokinet. 2005 ; 44 (11). 1117-1133 (Pubitemid 41483699)